In a move to bolster its cell therapies offering, Kite Pharma, a Gilead company agreed to collaborate with Shoreline Biosciences to develop novel cell therapies across a variety of cancer targets. The deal combines Kite’s experience in cell therapy development, commercialisation, and manufacturing to develop new allogeneic candidates for a range of hematologic malignancies with Shoreline’s expertise in induced pluripotent stem cells (iPSC) differentiation and genetic reprogramming. The deal is worth a total of US$2.3 B with Shoreline receiving an upfront payment as well as royalties upon achievement of certain development and commercial milestones.